DDX3 as a strongest prognosis marker and its downregulation promotes metastasis in colorectal cancer

Oncotarget

Volumn 6, Issue 21, 2015, Pages 18602-18612

  Su, Chia Yi ^a   Lin, Tsung Chieh ^a   Lin, Yuan Feng ^b   Chen, Ming Huang ^c   Lee, Chien Hsin ^a   Wang, Hsuan Yao ^d   Lee, Yu Chieh ^e   Liu, Yu Peng ^f   Chen, Chi Long ^b,g   Hsiao, Michael ^a  

^a GENOMICS RESEARCH CENTER   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^f KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^g TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Colorectal cancer; DDX3; E cadherin; Metastasis; Prognosis

Indexed keywords

DEAD BOX POLYPEPTIDE 3; TUMOR MARKER; UNCLASSIFIED DRUG; DDX3X PROTEIN, HUMAN; DEAD BOX PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CELL AGGREGATION; CELL INVASION; CELL MIGRATION; COHORT ANALYSIS; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DISTANT METASTASIS; DOWN REGULATION; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; OVARY CANCER; PHENOTYPE; PROTEIN EXPRESSION; RNA SEQUENCE; TUMOR PROMOTION; UPREGULATION; AGED; ANIMAL; COLORECTAL TUMOR; DNA MICROARRAY; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETIC DATABASE; GENETICS; HCT 116 CELL LINE; HT-29 CELL LINE; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; METABOLISM; METASTASIS; MIDDLE AGED; NONOBESE DIABETIC MOUSE; PATHOLOGY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE; SURVIVAL ANALYSIS; TUMOR CELL LINE;

AGED; ANIMALS; BIOMARKERS, TUMOR; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DATABASES, GENETIC; DEAD-BOX RNA HELICASES; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HT29 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; MIDDLE AGED; NEOPLASM METASTASIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84938802096     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4329     Document Type: Article

References (33)

1. Zhou Z, Licklider LJ, Gygi SP and Reed R. Comprehensive proteomic analysis of the human spliceosome. Nature. 2002; 419:182-185.
2. Yedavalli VS, Neuveut C, Chi YH, Kleiman L and Jeang KT. Requirement of DDX3 DEAD box RNA helicase for HIV-1 Rev-RRE export function. Cell. 2004; 119:381-392.
3. Chao CH, Chen CM, Cheng PL, Shih JW, Tsou AP and Lee YH. DDX3, a DEAD box RNA helicase with tumor growth-suppressive property and transcriptional regulation activity of the p21waf1/cip1 promoter, is a candidate tumor suppressor. Cancer Res. 2006; 66:6579-6588.
4. Chuang RY, Weaver PL, Liu Z and Chang TH. Requirement of the DEAD-Box protein ded1p for messenger RNA translation Science. 1997; 275:1468-1471.
5. Shih JW, Tsai TY, Chao CH and Wu Lee YH. Candidate tumor suppressor DDX3 RNA helicase specifically represses cap-dependent translation by acting as an eIF4E inhibitory protein. Oncogene. 2008; 27:700-714.
6. Lee CS, Dias AP, Jedrychowski M, Patel AH, Hsu JL and Reed R. Human DDX3 functions in translation and interacts with the translation initiation factor eIF3. Nucleic Acids Res. 2008; 36:4708-4718.
7. Rocak S and Linder P. DEAD-box proteins: the driving forces behind RNA metabolism. Nat Rev Mol Cell Biol. 2004; 5:232-241.
8. Fuller-Pace FV. DEAD box RNA helicase functions in cancer. RNA Biol. 2013; 10:121-132.
9. Botlagunta M, Vesuna F, Mironchik Y, Raman A, Lisok A, Winnard P, Jr., Mukadam S, Van Diest P, Chen JH, Farabaugh P, Patel AH and Raman V. Oncogenic role of DDX3 in breast cancer biogenesis. Oncogene. 2008; 27:3912-3922.
10. Sun M, Song L, Zhou T, Gillespie GY and Jope RS. The role of DDX3 in regulating Snail. Biochim Biophys Acta. 2011; 1813:438-447.
11. Miao X, Yang ZL, Xiong L, Zou Q, Yuan Y, Li J, Liang L, Chen M and Chen S. Nectin-2 and DDX3 are biomarkers for metastasis and poor prognosis of squamous cell/adenosquamous carcinomas and adenocarcinoma of gallbladder. Int J Clin Exp Pathol. 2013; 6:179-190.
12. Wu DW, Liu WS, Wang J, Chen CY, Cheng YW and Lee H. Reduced p21(WAF1/CIP1) via alteration of p53-DDX3 pathway is associated with poor relapse-free survival in early-stage human papillomavirus-associated lung cancer. Clin Cancer Res. 2011; 17:1895-1905.
13. Wu DW, Lee MC, Wang J, Chen CY, Cheng YW and Lee H. DDX3 loss by p53 inactivation promotes tumor malignancy via the MDM2/Slug/E-cadherin pathway and poor patient outcome in non-small-cell lung cancer. Oncogene. 2014; 33:1515-1526.
14. Lee CH, Lin SH, Yang SF, Yang SM, Chen MK, Lee H, Ko JL, Chen CJ and Yeh KT. Low/negative expression of DDX3 might predict poor prognosis in non-smoker patients with oral cancer. Oral Dis. 2014; 20:76-83.
15. Huang JS, Chao CC, Su TL, Yeh SH, Chen DS, Chen CT, Chen PJ and Jou YS. Diverse cellular transformation capability of overexpressed genes in human hepatocellular carcinoma. Biochem Biophys Res Commun. 2004; 315:950-958.
16. Chang PC, Chi CW, Chau GY, Li FY, Tsai YH, Wu JC and Wu Lee YH. DDX3, a DEAD box RNA helicase, is deregulated in hepatitis virus-associated hepatocellular carcinoma and is involved in cell growth control. Oncogene. 2006; 25:1991-2003.
17. Zhu J, Sanborn JZ, Benz S, Szeto C, Hsu F, Kuhn RM, Karolchik D, Archie J, Lenburg ME, Esserman LJ, Kent WJ, Haussler D and Wang T. The UCSC Cancer Genomics Browser. Nat Methods. 2009; 6:239-240.
18. Aguirre-Gamboa R, Gomez-Rueda H, Martinez-Ledesma E, Martinez-Torteya A, Chacolla-Huaringa R, Rodriguez-Barrientos A, Tamez-Pena JG and Trevino V. SurvExpress: an online biomarker validation tool and database for cancer gene expression data using survival analysis. PLoS One. 2013; 8:e74250.
19. Sheffer M, Bacolod MD, Zuk O, Giardina SF, Pincas H, Barany F, Paty PB, Gerald WL, Notterman DA and Domany E. Association of survival and disease progression with chromosomal instability: a genomic exploration of colorectal cancer. Proc Natl Acad Sci U S A. 2009; 106:7131-7136.
20. Opitz L, Salinas-Riester G, Grade M, Jung K, Jo P, Emons G, Ghadimi BM, Beissbarth T and Gaedcke J. Impact of RNA degradation on gene expression profiling. BMC Med Genomics. 2010; 3:36.
21. Gallego Romero I, Pai AA, Tung J and Gilad Y. RNA-seq: impact of RNA degradation on transcript quantification. BMC Biol. 2014; 12:42.
22. Botlagunta M, Krishnamachary B, Vesuna F, Winnard PT, Jr., Bol GM, Patel AH and Raman V. Expression of DDX3 is directly modulated by hypoxia inducible factor-1 alpha in breast epithelial cells. PLoS One. 2011; 6:e17563.
23. Bol GM, Raman V, van der Groep P, Vermeulen JF, Patel AH, van der Wall E and van Diest PJ. Expression of the RNA helicase DDX3 and the hypoxia response in breast cancer. PLoS One. 2013; 8:e63548.
24. Wang H, Kim S and Ryu WS. DDX3 DEAD-Box RNA helicase inhibits hepatitis B virus reverse transcription by incorporation into nucleocapsids. J Virol. 2009; 83:5815-5824.
25. Angus AG, Dalrymple D, Boulant S, McGivern DR, Clayton RF, Scott MJ, Adair R, Graham S, Owsianka AM, Targett-Adams P, Li K, Wakita T, McLauchlan J, Lemon SM and Patel AH. Requirement of cellular DDX3 for hepatitis C virus replication is unrelated to its interaction with the viral core protein. J Gen Virol. 2010; 91:122-132.
26. Ariumi Y, Kuroki M, Abe K, Dansako H, Ikeda M, Wakita T and Kato N. DDX3 DEAD-box RNA helicase is required for hepatitis C virus RNA replication. J Virol. 2007; 81:13922-13926.
27. Oshiumi H, Ikeda M, Matsumoto M, Watanabe A, Takeuchi O, Akira S, Kato N, Shimotohno K and Seya T. Hepatitis C virus core protein abrogates the DDX3 function that enhances IPS-1-mediated IFN-beta induction. PLoS One. 2010; 5:e14258.
28. McGivern DR and Lemon SM. Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer. Oncogene. 2011; 30:1969-1983.
29. Sun M, Zhou T, Jonasch E and Jope RS. DDX3 regulates DNA damage-induced apoptosis and p53 stabilization. Biochim Biophys Acta. 2013; 1833:1489-1497.
30. Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol. 2011; 6:479-507.
31. Suzuki K and Matsubara H. Recent advances in p53 research and cancer treatment. J Biomed Biotechnol. 2011; 2011:978312.
32. Chen HH, Yu HI, Cho WC and Tarn WY. DDX3 modulates cell adhesion and motility and cancer cell metastasis via Rac1-mediated signaling pathway. Oncogene. 2015; 34:2790-2800.
33. He X, Chen Z, Jia M and Zhao X. Downregulated E-cadherin expression indicates worse prognosis in Asian patients with colorectal cancer: evidence from meta-analysis. PLoS One. 2013; 8:e70858.